Therefore, it is possible that early loss of HRG2β during tumour development attenuates signalling through HER3 or HER4 and escalates cellular growth and angiogenesis, which ultimately leads to tumour progression and metastasis. The gene discussed is ERBB3; the disease is neoplasm.